09/18/2018

Recent Oncology Related Drug News

FDA Grants Priority Review to Keytruda to Treat Non-Small Cell Lung Cancer Subgroup

(Curetoday.com) Sept 12, 2018 - The Food and Drug Administration (FDA) granted priority review to Keytruda (pembrolizumab) monotherapy for the first-line treatment of patients with locally advanced or metastatic nonsquamous or squamous non-small cell lung cancer (NSCLC) whose tumors express PD-L1 without EGFR or ALK genomic tumor aberrations. READ ARTICLE